Latest News for: pd-l1

Edit

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or ...

Image Hastings Tribune 12 Feb 2026
SANTA CLARA, Calif.--(BUSINESS WIRE)--Feb 11, 2026-- ... .
Edit

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC) (Agilent Technologies Inc)

Public Technologies 11 Feb 2026
PD-L1 IHC 22C3 pharmDx, Code SK006, enables pathologists to assess PD-L1 expression at the time of diagnosis, supporting informed treatment decisions in a disease where therapeutic options remain limited for many patients.
Edit

Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

PR Newswire 10 Feb 2026
The grant of a patent will build upon Genprex's existing intellectual property foundation, which includes granted patents for the use of REQORSA in combination with PD-L1 antibodies in the U.S.
Edit

Leads Biolabs’ PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Dosed First Patient in New Indication, Paving a ...

GetNews 10 Feb 2026
Although PD-1/PD-L1-based immunotherapy in combination with chemotherapy has improved progression-free survival (PFS) and overall survival (OS) in patients with TNBC, these benefits are largely limited to the PD-L1-positive subgroup.
Edit

BWXT opens Melbourne IT center, pursues moon nuclear reactor for NASA

The Palm Beach Post 06 Feb 2026
A Fortune 1000 company that produces nuclear reactors and uranium fuel for the U.S ... NASA and the U.S. Department of Energy aim to deploy a nuclear reactor to the moon's surface by 2030. BWXT is considered a prime candidate ... You just can't ... 1 in Melbourne.
Edit

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

PR Newswire 30 Jan 2026
What differentiates NDL2 is that we are applying protein degradation to PD-L1 as one of the most clinically validated targets in cancer, while addressing a resistance mechanism not reached by existing ...
Edit

Why I Am Skeptical That Walz Will Acquiesce

Hot Air 26 Jan 2026
Ed wrote two excellent pieces today about the back and forth between Governor Tim Walz and President Trump.  ... 🚨 BREAKING ... 1 ... BREAKING ... 1 ... 2 ... Mutual aid from sympathetic locals (teachers providing cover, possible PD tip-offs on license plate lookups) ... .
Edit

Leads Biolabs’ PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Earns EU Orphan Drug Designation—Potential First-in-Class Therapy to ...

GetNews 23 Jan 2026
Opamtistomig (LBL-024) is a potential first-in-class bispecific antibody that simultaneously targets PD-L1 and the co-stimulatory receptor 4-1BB ... for PD-L1 and 4-1BB with an optimized affinity ratio.
Edit

Motor Mouth: The inevitable rise of hybrid cars

Driving 23 Jan 2026
Among U.S. consumers, interest in hybrid vehicles continues to grow at a pace “that indicates this is more than just a transition to electric vehicles.” At least, so says S&P Global. According to S&P’s. “What’s fueling rising U.S ... EV owners ... ICE owners ... ).
Edit

Callahan: Why Drake Maye’s timing will decide AFC title game and more Patriots thoughts

Boston Herald 23 Jan 2026
Getting your Trinity Audio player ready. Welcome to the Friday Five, postseason edition! ... Ready, set, football. 1. Set your stopwatches. More than matchups, more than scheme, the AFC Championship Game should come down to time ... covering quick passes ... 2 ... Kuhr.
Edit

Painter's passion helps villagers realize their dreams on rural canvases

China Daily 22 Jan 2026
ZHENGZHOU — A photo of a group of elderly villagers beaming with joy in front of the Tian'anmen Rostrum, their faces radiating with a warm sense of excitement, recently went viral online. A closer look reveals a heartwarming scene ... 1/3 Next.
×
×
×
×